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ABSTRACT: The glycosylation in recombinant monoclonal antibody (rMab) drugs is a major
concern in the biopharmaceutical industry as it impacts the drugs’ many attributes. Characterization is
important but complicated by the intricate structures, microheterogeneity, and the limitations of
current tools for structural analysis. In this study, we developed a liquid chromatography−mass
spectrometry (LC−MS) N-glycan library based on eight commercial rMab drugs. A library of over 70
structures was developed for the rapid characterization of rMab. N-Glycans were separated on a
porous graphitized carbon (PGC) column incorporated on a chip and then analyzed by an
electrospray ionization hybrid quadrupole time-of-flight (ESI-Q-TOF) MS. The retention time and
accurate mass for each N-glycan were recorded in the library. The complete structures were obtained
through exoglycosidase sequencing. The results showed that most of the N-glycans between different
antibodies are nearly the same with different abundances. The utility of this library enables one to
identify structures in a rapid manner by matching LC retention times and accurate masses.
Recombinant monoclonal antibody (rMab) drugs haveemerged as a powerful class of biopharmaceuticals. Their
specificity toward target antigens makes them effective
treatments for cancers and other chronic diseases.1−4 rMab-
based drugs have multiple functions including blocking the
signal transduction of tumor cells to proliferate, activating the
immune system to kill tumor cells, and carrying cancer drugs or
radiation targets to tumor cells.3 The first licensed rMab drug
was muromonab in 1986, and it is estimated that approximately
30% of the new drugs approved in the next decade will be rMab
drugs.1,3,5−8 Currently, there are more than 30 approved rMab
drugs and hundreds of new rMab drug candidates under clinical
trials.5 All currently approved rMab drugs are based on IgG and
are usually manufactured from Chinese hamster ovary (CHO),
mouse myeloma NS0, and mouse myeloma Sp2/0 cell
lines.1,3,5−10
rMab is composed of two identical light chains and two
identical heavy chains. The antibody contains three domains:
the antigen binding (Fab), the hinge region, and the fragment
crystallizable (Fc) domain.9,10 There is one N-glycosylation site
(Asn 297) found in the Fc region on both identical heavy
chains. Some rMabs may contain oligosaccharides in the Fab
region.11,12 Although the oligosaccharides in the Fc region only
account for 2−3% of the total protein mass, they have a major
affect in functions related to drug efficacy, pharmacokinetics,
stability, and immunogenicity.10,13−15 For example, the effector
function of the deglycosylated or aglycosylated rMab is found
to be severely compromised or ablated,15 while an increased
level of N-glycolylneuraminic acid (NeuGc) produces shorter
half-life.16 In general, specific glycoforms can increase or
decrease the drug efficacy, although the precise reason may not
always be clearly understood.14,15,17 Therefore, deep structural
characterization of N-glycosylation of rMab is essential for drug
development and production. However, the microheterogene-
ity of the glycans, their diverse compositions, the large number
of isomeric structures, and the large variations in abundances all
make extensive glycan characterization of rMab a slow and
tedious process.18,19 Furthermore, because the best known
pharmaceuticals were discovered much earlier when glyco-
analytics was not as advanced, the threshold for characterization
was much lower. Glycan analysis was focused on three
components known as G0F, G1F, and G2F.20,21 However,
the coming tide of biosimilars and follow-on biologics will
require considerably better glycan characterization.
In this report, we describe a method for the rapid
characterization of rMab glycosylation using a detailed N-
glycan library exclusively for rMab. The library was constructed
using commercial rMab drugs including trastuzumab, bevaci-
zumab, rituximab, cetuximab, panitumumab, infliximab, ofatu-
mumab, and eculizumab. NanoLC-Chip-Q-TOF analysis,
exoglycosidase sequencing, and a reference N-glycan library
built from human serum glycoproteins were used to build the
rMab N-glycan library.22,23 All the N-glycans were separated on
the nanoLC-chip with a PGC column. Owing to the excellent
separation performance of the PGC medium and the high mass
accuracy of TOF MS, each N-glycan isomer has a unique
retention time and accurate mass.24−27 The reproducible
retention time and accurate mass are used to rapidly identify
unknown glycans in the rMab.25,28−30
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■ EXPERIMENTAL SECTION
Chemicals and Reagents. All the rMab drugs were
obtained from UC Davis Medical Center. Peptide, N-
Glycosidase F (PNGase F), and exoglycosidases, α(2-3)-
neuraminidase (sialidase), α(1-2,3)mannosidase, and β-N-
acetyl glucosaminidase (β-GlcNAcase), were obtained from
New England Biolabs (Ipswich, MA); β(1-4)Galactosidase and
α(1-3,4)fucosidase were obtained from Prozyme (Hayward,
CA). Dithiothreitol (DTT) was purchased from Promega
(Madison, WI). Sodium borohydride was purchased from
Sigma-Aldrich (St. Louis, MO). All reagents are of analytical or
HPLC grade.
N-Glycan Release, Reduction, and Purification. N-
glycans were released from rMab using standard PNGase F
methods.31 Briefly, rMab drugs were first denatured by DTT
and then treated with PNGase F to release N-glycans. Free N-
glycans were then purified by solid phase extraction (SPE)
using graphitized carbon cartridges (GCC) (Alltech Associated,
Deerfield, IL) in an automated manner using a Gilson GX-274
ASPEC robot liquid handler. Purified N-glycans were reduced
by 1 M NaBH4 in a water bath at 65 °C for 2 h. Reduced N-
glycans were desalted and enriched again with GCC-SPE to
remove salts from the reduction.
N-Glycan Preparation. For simplicity, the compounds
were first separated as much as possible using HPLC on a
Hypercarb PGC column (Thermo Scientific) (100 mm × 0.5
mm i.d., 5 μm particle size) with a Hewlett-Packard series 1100
HPLC system. Fractions were collected in 1 min intervals. A
binary solvent system was used comprising of 0.1% formic acid
(FA) in 3% ACN in water (v/v) as solvent A and 0.1% FA in
90% ACN in water (v/v) as solvent B. N-Glycans were
separated by the gradient: 0−25 min, 0%−15% B; 25.01−50
min, 15−40% B; 50−70 min, 40−100% B at a flow rate of 0.30
mL/min. Fractions were collected in a 70 min run, dried, and
reconstituted with nanopure water.
nanoLC-Chip-Q-TOF MS of N-Glycan. Each fraction was
monitored for N-glycan content using an Agilent 6520
nanoLC-Chip-Q-TOF equipped with an Agilent 1200 series
Figure 1. Illustration of the identification procedure for antibody N-glycans using a previously annotated reference library. (a) Extracted compound
chromatogram (ECC) of composition N54110 from an N-glycan reference library and from the rMab. Four isomers were found in the reference
library for the monofucosylated monosialylated structure. On the basis of the similarities in accurate mass and retention times, the structure was
determined as shown (inset). (b) Two isomers with similar retention times corresponding to monofucosylated biantennary structures. The rMab
glycans matched those corresponding to the library and the structures were determined (inset). (c) Two isomers corresponding to terminal
monogalactosylated structures. The structures were determined and are shown (inset). (d) A bisecting GlcNAc with monosialylated and
monofucosylated structure as determined by comparison to the reference library. Compounds were reduced to the alditol prior to the LC−MS
analysis. Symbolic N-glycan structures correspond to (blue ■) N-acetylglucosamine, (green ●) mannose, (yellow ●) galactose, (○) hexose, (red
▲) fucose, (purple ◆) N-acetyl neuraminic acid, (◊) N-glycolylneuraminic acid. Linkages are provided at the glycosidic bond.
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nano-LC system. The nano-LC system employs a binary
solvent system consisting of solvent A, 0.1% formic acid (FA)
in 3% ACN in water (v/v), and solvent B, 0.1% FA in 90%
ACN in water (v/v). The enrichment column (40 nL PGC)
and analytical column (75 μm × 43 mm, 5 μm particle size,
PGC) are integrated on a chip, which is placed in the chip−
cube interface. The N-glycans were concentrated on the
enrichment column for 5 min with 100% solvent A. The
instrument was then switched to analysis mode, thereby
delivering the N-glycans from the enrichment column to the
analytical column for separation. The gradient used was 0% B,
0−2.5 min; 0−16% B, 2.5−20 min; 16−44% B, 20−30 min;
44−100% B, 30−35 min; and 100% B, 35−45 min followed by
pure A for 20 min as an equilibration. All MS spectra were
acquired in positive mode. The instrument was calibrated prior
to use to yield mass accuracies below 5 ppm for MS and 20
ppm for MS/MS.
Tandem MS and Exoglycosidase Digestion. Tandem
MS analysis was used to guide the exoglycosidase digestions,
which in turn were used to elucidate the complete structures.
Tandem MS spectra were acquired through collision induced
dissociation (CID) by nanoLC-Chip-Q-TOF in the auto MS/
MS mode. The applied collision energy depends on the m/z of
each compound according to the formula:
= −V m z1.8 V(( / )/100 Da) 3.6 Vcollision
where the slope and intercept were optimized to obtain
maximum fragment information.28
Buffers for the reaction were prepared by adding glacial acetic
acid to 0.1 M ammonium acetate to achieve the desired pH for
each enzyme. Reaction time varied from 1 to 24 h at 37 °C
depending on the specificity of the enzyme. Reaction
conditions for each enzyme are listed in the Supporting
Information (Table S2). It is important to point out that the
enzyme specificity varied with reaction times. The optimal
times were determined in previous studies.32 The enzymes
included α(2-3)neuraminidase (sialidase), α(1-2,3)-
mannosidase, β-N-acetylglucosaminidase (GlcNAcase), β(1-
4)galactosidase, and α(1-3,4)fucosidase.
■ RESULTS AND DISCUSSION
Structural Identification of rMab N-Glycans Using a
Human Serum Glycoprotein N-Glycan Library. In a
previous study, we published N-glycan structures from a
group of the most abundant glycoproteins in serum.22 Those
glycan structures were used to identify some of the structures in
the antibodies. The N-glycan library is developed based on
released and reduced N-glycans from serum glycoproteins,
separated on a PGC column, and analyzed by TOF MS. The
linkages were elucidated through a combination of exoglyco-
sidase sequencing, LC, LC−MS, and tandem MS. The
comprehensive N-glycan library is composed of complete
structures with associated LC retention times, accurate masses,
and relative abundances. The mass accuracy of Q-TOF MS
used in this study is 5 ppm and the retention time coefficient
variance (CV) of the nano-Chip-LC is within 0.6% when run
on the same day, which assured the robustness of this approach.
The majority of the N-glycans from the eight commercial rMab
drugs were characterized by matching the LC retention times
and accurate masses with the structures in a previously
annotated reference library.22
Figure 1 illustrates how the structures were assigned for
rMab via LC retention time and accurate mass. Reference
compounds in the library are obtained from serum
glycoproteins. Shown in Figure 1 are extracted compound
chromatograms (ECC) of several compounds from the
reference library and from the antibody drug. In Figure 1a,
the upper chromatogram shows the four isomers of N54110 in
the reference compound. The nomenclature uses the letter “N”
for N-glycan with each digit representing the composition
Hex:HexNac:Fuc:NeuAc:NeuGc. The mass spectrometer does
not distinguish between mannose and galactose (Hex) or
between N-acetylgalactose and N-acetylglucose amine (Hex-
NAc). However, fucose (Fuc) as well as N-acetylneuraminic
acid (NeuAc) and N-glycolylneuraminic acid (NeuGc) are
readily determined by mass. NeuGc is not typically found in
humans but is found in other mammals.33 The abundances of
NeuGc residues in rMab are low but measurable and are due to
the production in CHO/SP 20/NS0 cells.21 The lower case
letters following the numbers represent the order in which the
compound was elucidated and roughly follows its relative
abundance in serum or its relative abundance in rMab for those
not present in serum. The lower chromatogram in Figure 1a
shows the ECC of one isomer of N54110 found in
Trastuzumab that is aligned with a structure originally found
in serum glycoproteins and whose structure is known.
Therefore, the compound in rMab is identified as the same
structure N54110a in the N-glycan library. The symbolic
structure is shown in the inset. Figure 1b demonstrates the
identification of N44100a and N44100b in rMab. The complete
structures for N44100a and N44100b are given with the isomer
“a” having a Gal on the 1-6 arm and isomer “b” with the
terminal Gal on the 1-3 arm (structure inset). N44000a and
N44000b in Figure 1c and N55110a in Figure 1d were
identified in the same way.
In order to further evaluate the robustness of using LC
retention times to identify isomers from the N-glycan library,
the retention time shift between different runs within 1 day of
rMab N-glycans was examined. The retention time repeatability
was high with the largest shift in retention time correspond to
approximately 0.1 min in a 60 min gradient (Figure 2);
however, the shifts are generally much less. This corresponding
CV was calculated to be ∼0.6%.
Figure 2. Chromatograms of 13 overlaid injections showing the major
N-glycans from Panitumumab acquired on nanoLC-Chip-TOF.
Injections were performed consecutively. The largest variation in
retention time corresponded to 0.10 min.
Analytical Chemistry Technical Note
dx.doi.org/10.1021/ac501102t | Anal. Chem. 2014, 86, 5661−56665663
Structural Elucidation Using Exoglycosidase Sequenc-
ing. Additional exoglycosidase sequencing was performed to
deduce the complete structures of around 30 percent of N-
glycans in rMab that were not determined based on the current
N-glycan library because they are either absent or in very low
abundance. The enzymes are sufficiently specific to linkages for
specific digestion periods as previously reported in our
laboratory.29,32 In order to eliminate the interference resulting
from isomeric structures during the digestion, off-line HPLC
fractionation was performed to isolate the compounds as much
as possible. Fractionating the compounds also minimized
overlap between enzymatic digestion products. Figure 3
demonstrates the determination of two isomers of N33100
obtained in two separate fractions, using α(1-2,3)mannosidase.
The upper chromatograms in Figure 3a,b show the two isomers
before enzyme digestion (MS spectra are the inset). The lower
chromatograms show two digestion products with two distinct
masses (MS spectra are the inset). After 24 h of α(1-
2,3)mannosidase digestion, the isomer in Figure 3a lost one
mannose while the isomer in Figure 3b remained the same
mass thereby showing that the first has the terminal mannose
on the 1-6 arm while the second has the terminal mannose on
the 1-3 arm. The same method employing enzyme digestion
monitored by LC−MS were applied to deduce the other
structures in rMabs. The retention times of all the new N-
glycans were noted and used for future structural identification
in other rMabs.
N-Glycan Library for rMab. The completed N-glycan
library for rMab includes all the N-glycans from the commercial
rMab drugs detected by nanoLC−Q-TOF MS. Relative
abundances were acquired for each N-glycan based on the
integration of the ion abundances associated with each peak
and normalized to the total ion counts of all the N-glycans of
each rMab. The rMab N-glycan library contains more than 70
entries spanning 3 orders of magnitude in abundances. There
are 25 fully elucidated structures, with the remainder being
partially elucidated structures. The latter group is of low
abundances and could not be isolated in sufficient amounts for
complete elucidation. The fraction of fully elucidated structures
represents more than 80−90% of the total abundances for each
rMab. This group represents a significantly more comprehen-
sive one than the standard G0F, G1F, and G2F.11,12,20,34−36 N-
Glycans with NeuGc residues were also included in the library,
and however their abundances were usually less than 5% of the
most abundant species.
Table S1 in the Supporting Information presents the
comprehensive library, with systematic names, accurate masses,
symbolic structures annotated with linkage information, and
associated rMab drugs. The top 10 N-glycans were found in all
rMab drugs included in this study. Most isomers were well
separated and characterized. The most abundant compounds
generally contained complete structures and are shown with all
linkage information. The common structures referred to as
G1F, G0F-GlcNAc, G1 correspond to the respective pairs
N44100a and N44100b, N33100a and N33100b, and N44000a
and N44000b.11,12,20,21,35−37 The extracted chromatograms
provide relative quantitative information. For example, the
two isomers, N44100a and N44100b have significantly different
abundances with N44100a (Gal on the 1-6 antenna) almost
twice as abundant as N44100b (Gal on the 1-3 antenna) in
Trastuzumab, Bevacizumab, Rituximab, Cetuximab, Infliximab,
Ofatumumab, and Eculizumab. In contrast, N44100b is twice as
abundant as N44100a in Panitumumab (Figure 4). The most
Figure 3. Chromatograms (with MS inset) produced during
exoglycosidase sequencing of two isomers with composition N33100
(1261.50 Da, neutral mass). (a) The upper chromatogram shows
isomer N33100a before digestion. The representation identifies the
uncertainty in the structure. The lower panel includes the ECC of the
neutral mass 1261.50 and 1099.45 Da. A single mannose was lost after
24-h digestion with α(1-2,3)mannosidase (MS inset) suggesting an
uncapped mannose structure on the 1-3 antenna. The results show
that the terminal GlcNAc is on the 1-6 branch. (b) The upper
chromatogram shows isomer N3310b before enzyme digestion (MS
inset). This compound was analyzed at the same time as the other
isomer. There was no loss in signal or new smaller homologue
produced when the compound was reacted with α(1-2,3)
mannosidase.
Figure 4. Relative abundances of N44100a (G1aF) and N44100b
(G1bF) for each rMab.
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abundant N-glycans generally corresponded to G2F, G1F, G2F,
and Man5 as stated in previous reports.12,20,21,34−38 However,
we find that other N-glycans may be as abundant (Table 1).
For example, N74100a is even more abundant than N44100b
(G1bF) and N54100a (G2F) in Cetuximab. Similar observa-
tions are found with Infliximab, Ofatumumab, and Panitumu-
mab, where noncommon structures were more abundant than
those commonly monitored. Cetuximab and Infliximab
(produced in Sp2/0 cell lines) and Ofatumumab (produced
in NS0 cell lines) are found to have a higher percent of NeuGc-
containing N-glycans (6.81%, 6.51%, and 5.16%, respectively)
compared to Trastuzumab, Bevacizumab, Rituximab, and
Panitumumab (0%, 4.15%, 3.67%, and 0%, respectively),
which are produced in CHO cell lines. This finding is
consistent with a previous report that CHO cell lines may
yield lower abundances of NeuGc-containing N-glycans.16
■ CONCLUSION
We constructed an N-glycan library containing complete
structures for rapid and high-throughput glycan analysis of
rMab. This library provides a reference for the rapid
identification of glycans in rMab and possibly other biologics
that are produced with the same cell lines. The reproducible LC
retention times and accurate masses are useful markers for
identifying structures. It no longer requires further time-
consuming N-glycan isolation and extensive exoglycosidase
sequencing.22,29,39 The tandem mass spectra for each N-glycan
were also recorded in the library but were seldom used for
further identification (Figure S1 in the Supporting Informa-
tion). For the utility of the N-glycan Library, a 0.1 min
retention time window and 20 ppm mass accuracy window are
suggested as the minimum criteria for identification.22,29,39
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